|
|
|
|
|
|
|
|
|
|
|
|
|
|
Previous: ABBOTT LABORATORIES, 10-Q, EX-12, 2000-11-13 |
Next: ACCEL INTERNATIONAL CORP, NT 10-Q, 2000-11-13 |
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONDENSED CONSOLIDATED STATEMENT OF EARNINGS FOR THE NINE MONTHS ENDED SEPTEMBER
30, 2000, AND THE CONDENSED CONSOLIDATED BALANCE SHEET AS OF SEPTEMBER 30, 2000,
AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
<CURRENCY> U.S. DOLLARS
<S> <C>
<PERIOD-TYPE> 9-MOS
<FISCAL-YEAR-END> DEC-31-2000
<PERIOD-START> JAN-01-2000
<PERIOD-END> SEP-30-2000
<EXCHANGE-RATE> 1
<CASH> 878,115
<SECURITIES> 89,526
<RECEIVABLES> 2,208,437
<ALLOWANCES> 178,467
<INVENTORY> 1,732,461
<CURRENT-ASSETS> 6,971,289
<PP&E> 9,980,201
<DEPRECIATION> 5,239,617
<TOTAL-ASSETS> 14,980,161
<CURRENT-LIABILITIES> 4,284,105
<BONDS> 1,076,316
0
0
<COMMON> 2,136,242
<OTHER-SE> 6,177,419
<TOTAL-LIABILITY-AND-EQUITY> 14,980,161
<SALES> 10,041,226
<TOTAL-REVENUES> 10,041,226
<CGS> 4,542,206
<TOTAL-COSTS> 4,542,206
<OTHER-EXPENSES> 1,001,342<F1>
<LOSS-PROVISION> (46,813)
<INTEREST-EXPENSE> 90,278
<INCOME-PRETAX> 2,784,354
<INCOME-TAX> 751,776
<INCOME-CONTINUING> 2,032,578
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 2,032,578
<EPS-BASIC> 1.31
<EPS-DILUTED> 1.30
<FN>
<F1>OTHER EXPENSES CONSISTS OF RESEARCH AND DEVELOPMENT EXPENSE.
</FN>
</TABLE>
|
|